JP2020536121A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020536121A5 JP2020536121A5 JP2020539153A JP2020539153A JP2020536121A5 JP 2020536121 A5 JP2020536121 A5 JP 2020536121A5 JP 2020539153 A JP2020539153 A JP 2020539153A JP 2020539153 A JP2020539153 A JP 2020539153A JP 2020536121 A5 JP2020536121 A5 JP 2020536121A5
- Authority
- JP
- Japan
- Prior art keywords
- composition according
- imeglimin
- day
- administered
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 claims 22
- GFICWFZTBXUVIG-SCSAIBSYSA-N imeglimin Chemical compound C[C@H]1NC(N(C)C)=NC(N)=N1 GFICWFZTBXUVIG-SCSAIBSYSA-N 0.000 claims 12
- 229950005411 imeglimin Drugs 0.000 claims 12
- 230000037396 body weight Effects 0.000 claims 8
- 208000038003 heart failure with preserved ejection fraction Diseases 0.000 claims 5
- 239000003814 drug Substances 0.000 claims 3
- -1 DPP-4 inhibitor Proteins 0.000 claims 2
- 208000001145 Metabolic Syndrome Diseases 0.000 claims 2
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 2
- OGYGFUAIIOPWQD-UHFFFAOYSA-N 1,3-thiazolidine Chemical compound C1CSCN1 OGYGFUAIIOPWQD-UHFFFAOYSA-N 0.000 claims 1
- 229940077274 Alpha glucosidase inhibitor Drugs 0.000 claims 1
- 229940123208 Biguanide Drugs 0.000 claims 1
- XNCOSPRUTUOJCJ-UHFFFAOYSA-N Biguanide Chemical compound NC(N)=NC(N)=N XNCOSPRUTUOJCJ-UHFFFAOYSA-N 0.000 claims 1
- 108010088406 Glucagon-Like Peptides Proteins 0.000 claims 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims 1
- 102000004877 Insulin Human genes 0.000 claims 1
- 108090001061 Insulin Proteins 0.000 claims 1
- 208000008589 Obesity Diseases 0.000 claims 1
- 108091006277 SLC5A1 Proteins 0.000 claims 1
- 108091006269 SLC5A2 Proteins 0.000 claims 1
- 102000000070 Sodium-Glucose Transport Proteins Human genes 0.000 claims 1
- 108010080361 Sodium-Glucose Transport Proteins Proteins 0.000 claims 1
- 102000058090 Sodium-Glucose Transporter 1 Human genes 0.000 claims 1
- 102000058081 Sodium-Glucose Transporter 2 Human genes 0.000 claims 1
- 229940100389 Sulfonylurea Drugs 0.000 claims 1
- 239000003888 alpha glucosidase inhibitor Substances 0.000 claims 1
- 229940127003 anti-diabetic drug Drugs 0.000 claims 1
- 239000003472 antidiabetic agent Substances 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 229940090124 dipeptidyl peptidase 4 (dpp-4) inhibitors for blood glucose lowering Drugs 0.000 claims 1
- 239000003136 dopamine receptor stimulating agent Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000012458 free base Substances 0.000 claims 1
- 201000001421 hyperglycemia Diseases 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 claims 1
- 229940125396 insulin Drugs 0.000 claims 1
- 208000029077 monogenic diabetes Diseases 0.000 claims 1
- 235000020824 obesity Nutrition 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 229940127557 pharmaceutical product Drugs 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- YROXIXLRRCOBKF-UHFFFAOYSA-N sulfonylurea Chemical class OC(=N)N=S(=O)=O YROXIXLRRCOBKF-UHFFFAOYSA-N 0.000 claims 1
- 230000001052 transient effect Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762566668P | 2017-10-02 | 2017-10-02 | |
| US62/566,668 | 2017-10-02 | ||
| PCT/IB2018/057648 WO2019069230A1 (en) | 2017-10-02 | 2018-10-02 | METHODS OF TREATING CARDIAC INSUFFICIENCY WITH PRESERVED EJECTION FRACTION |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020536121A JP2020536121A (ja) | 2020-12-10 |
| JP2020536121A5 true JP2020536121A5 (enExample) | 2021-12-02 |
Family
ID=63963334
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020539153A Pending JP2020536121A (ja) | 2017-10-02 | 2018-10-02 | 駆出率が保持された心不全を治療する方法 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US11617754B2 (enExample) |
| EP (1) | EP3691650A1 (enExample) |
| JP (1) | JP2020536121A (enExample) |
| KR (1) | KR20200102982A (enExample) |
| CN (1) | CN111163782A (enExample) |
| BR (1) | BR112020006472A2 (enExample) |
| CA (1) | CA3078163A1 (enExample) |
| IL (1) | IL273723A (enExample) |
| MX (1) | MX2020003243A (enExample) |
| TW (1) | TW201924689A (enExample) |
| WO (1) | WO2019069230A1 (enExample) |
| ZA (1) | ZA202002292B (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3691650A1 (en) | 2017-10-02 | 2020-08-12 | Poxel | Methods of treating heart failure with preserved ejection fraction |
| MY203360A (en) | 2018-06-06 | 2024-06-26 | Metavant Sciences Gmbh | Methods of treating subjects having diabetes with chronic kidney disease |
| CA3103324A1 (en) | 2018-06-14 | 2019-12-19 | Poxel | Film-coated tablet comprising a triazine derivative for use in the treatment of diabetes |
| CN121287190A (zh) * | 2021-09-07 | 2026-01-09 | 深圳迈瑞生物医疗电子股份有限公司 | 一种超声波数据的处理方法、成像装置 |
| CN116440075B (zh) * | 2023-06-01 | 2025-05-06 | 苏州中化药品工业有限公司 | 一种干混悬剂及其制备方法 |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2804113B1 (fr) | 2000-01-26 | 2004-06-18 | Lipha | Derives animes de dihydro-1,3,5-triazine et leurs applications en therapeutique |
| FR2853650B1 (fr) | 2003-04-10 | 2006-07-07 | Merck Sante Sas | Procede de dedoublement d'amines utiles pour le traitement de desordres associes au syndrome d'insulino-resistance |
| FR2896159B1 (fr) | 2006-01-13 | 2008-09-12 | Merck Sante Soc Par Actions Si | Combinaison de derives de triazine et d'agents sensibilisateurs a l'insuline. |
| FR2896161B1 (fr) | 2006-01-13 | 2008-04-04 | Merck Sante Soc Par Actions Si | Utilisation de derives de triazines pour fabriquer un medicament ayant un effet cicatrisant ou angiogenique. |
| FR2896157B1 (fr) | 2006-01-13 | 2008-09-12 | Merck Sante Soc Par Actions Si | Combinaison de derives de triazine et d'agents de stimulation de secretion d'insuline. |
| DE102008007314A1 (de) | 2008-02-02 | 2009-08-06 | Merck Patent Gmbh | Verfahren zur Herstellung von 3,6-Dihydro-1,3,5-triazinderivaten |
| US20110124860A1 (en) | 2008-05-23 | 2011-05-26 | Aubourg Stephanie | Process for the synthesis of 3,6-dihydro-1,3,5-triazine derivatives |
| SI2344435T1 (sl) | 2008-07-29 | 2016-05-31 | Poxel | Proces izolacije enantiomernih spojin iz enantiomernih mešanic s kristalizacijo nadzorovano z velikostjo delcev |
| ES2530223T3 (es) | 2008-12-12 | 2015-02-27 | Poxel S.A.S. | Combinación de insulina con derivados de triazina y su uso para tratar la diabetes |
| JP5485292B2 (ja) | 2008-12-12 | 2014-05-07 | ポクセル・エスアーエス | Ａｍｐｋ活性に関連する疾患を処置するためのテトラヒドロトリアジン化合物 |
| US8742102B2 (en) | 2009-03-26 | 2014-06-03 | Poxel | Process for enantiomeric separation of racemic dihydro-1,3,5 triazines via preferential crystallization |
| FR2948027A1 (fr) | 2009-07-17 | 2011-01-21 | Merck Sante Sas | Derives amines de dihydro-1,3,5-triazine pour leur utilisation dans le traitement des maladies associees a une ischemie et/ou une reperfusion |
| WO2011154496A1 (en) | 2010-06-09 | 2011-12-15 | Poxel | Treatment of type 1 diabetes |
| TWI436768B (zh) * | 2010-06-09 | 2014-05-11 | Poxel | 第２型糖尿病之治療 |
| EP2646422B1 (en) | 2010-12-01 | 2015-07-08 | Poxel | Separation of triazine derivatives enantiomers using tartaric acid |
| US9211263B2 (en) | 2012-01-06 | 2015-12-15 | Elcelyx Therapeutics, Inc. | Compositions and methods of treating metabolic disorders |
| WO2014160524A1 (en) * | 2013-03-14 | 2014-10-02 | The Trustees Of The University Of Pennsylvania | Cardio- metabolic and cascular effects of glp-1 metabolites |
| CA2812519A1 (en) | 2013-04-05 | 2014-10-05 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
| US9526728B2 (en) | 2014-02-28 | 2016-12-27 | Boehringer Ingelheim International Gmbh | Medical use of a DPP-4 inhibitor |
| WO2016077126A1 (en) | 2014-11-10 | 2016-05-19 | Merck Sharp & Dohme Corp. | Sglt-2 inhibitors for treating metabolic disorders in patients with renal impairment or chronic kidney disease |
| KR20230111262A (ko) * | 2016-03-16 | 2023-07-25 | 베링거 인겔하임 인터내셔날 게엠베하 | 엠파글리플로진을 포함하는 약제학적 조성물 및 이의용도 |
| EP3691650A1 (en) | 2017-10-02 | 2020-08-12 | Poxel | Methods of treating heart failure with preserved ejection fraction |
| MY203360A (en) | 2018-06-06 | 2024-06-26 | Metavant Sciences Gmbh | Methods of treating subjects having diabetes with chronic kidney disease |
-
2018
- 2018-10-02 EP EP18792513.6A patent/EP3691650A1/en not_active Withdrawn
- 2018-10-02 KR KR1020207011597A patent/KR20200102982A/ko not_active Ceased
- 2018-10-02 WO PCT/IB2018/057648 patent/WO2019069230A1/en not_active Ceased
- 2018-10-02 JP JP2020539153A patent/JP2020536121A/ja active Pending
- 2018-10-02 CA CA3078163A patent/CA3078163A1/en active Pending
- 2018-10-02 MX MX2020003243A patent/MX2020003243A/es unknown
- 2018-10-02 TW TW107134796A patent/TW201924689A/zh unknown
- 2018-10-02 CN CN201880063705.4A patent/CN111163782A/zh active Pending
- 2018-10-02 US US16/652,911 patent/US11617754B2/en active Active
- 2018-10-02 BR BR112020006472-6A patent/BR112020006472A2/pt not_active IP Right Cessation
-
2020
- 2020-03-31 IL IL273723A patent/IL273723A/en unknown
- 2020-05-04 ZA ZA2020/02292A patent/ZA202002292B/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020033360A5 (enExample) | ||
| JP6676108B2 (ja) | ２型糖尿病の処置のためのリキシセナチド及びメトホルミン | |
| IL274943B2 (en) | Combination of a 4-pyrimidinsulfamide derivative with an SGLT-2 inhibitor for the treatment of endothelin-related diseases | |
| TWI455723B (zh) | 納曲酮及安非他酮於治療超重或肥胖病患之用途 | |
| KR101900520B1 (ko) | 복합 조성물 | |
| EP2523557B1 (en) | Methods of providing weight loss therapy in patients with major depression | |
| ES3009607T3 (en) | Nk-1 antagonist compositions and methods for use in treating depression | |
| NZ745778A (en) | Use of masitinib for treatment of an amyotrophic lateral sclerosis patient subpopulation | |
| JP2016516016A5 (enExample) | ||
| ES3062720T3 (en) | Sublingual epinephrine tablets | |
| JP5757544B2 (ja) | 癌治療に用いられるベムラフェニブとインターフェロンを含む併用療法 | |
| US20220151960A1 (en) | Treatment of symptoms associated with female gastroparesis | |
| JP2018509419A5 (enExample) | ||
| JP2024010018A (ja) | うつ病を治療するための組成物および方法 | |
| JP2016505050A5 (enExample) | ||
| WO2013028882A1 (en) | Treatment of symptoms associated with female gastroparesis | |
| JP2020500930A5 (enExample) | ||
| Provilus et al. | Weight gain associated with antidiabetic medications | |
| Forner et al. | Pharmacotherapy for the Management of Overweight and Obesity | |
| JP2022540198A (ja) | 組合せ | |
| CN116157132A (zh) | 一种降低血糖的组合、应用和方法 | |
| Pandit et al. | Obesity context of type 2 diabetes and medication perspectives | |
| US20250195455A1 (en) | Combination nasal and oral therapy for weight loss | |
| HK40111721A (en) | Combination nasal and oral therapy for weight loss | |
| CN108159032A (zh) | 二甲双胍在制备预防和/或治疗阿片类毒品成瘾药物中的应用和药物及制备方法 |